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Abstract— Background: Functional and molecular changes 
often precede gross anatomical changes, so early assessment of a 
tumor’s functional and molecular response to therapy can help 
reduce a patient’s exposure to the side effects of ineffective 
chemotherapeutics or other treatment strategies.  Objective: Our 
intent was to test the hypothesis that an ultrasound microvascular 
imaging approach might provide indications of response to 
therapy prior to assessment of tumor size.  Methods: Mice bearing 
clear-cell renal cell carcinoma xenograft tumors were treated with 
antiangiogenic and Notch inhibition therapies.  An ultrasound 
measurement of microvascular density was used to serially track 
the tumor response to therapy.  Results: Data indicated that 
ultrasound-derived microvascular density can indicate response to 
therapy a week prior to changes in tumor volume and is strongly 
correlated with physiological characteristics of the tumors as 
measured by histology (ρ=0.75).  Furthermore, data demonstrated 
that ultrasound measurements of vascular density can determine 
response to therapy and classify between-treatment groups with 
high sensitivity and specificity.   Conclusion/Significance: Results 
suggests that future applications utilizing ultrasound imaging to 
monitor tumor response to therapy may be able to provide earlier 
insight into tumor behavior from metrics of microvascular density 
rather than anatomical tumor size measurements. 
 
Index Terms— microvasculature, angiogenesis, ultrasound, 
contrast agents, response to therapy, acoustic angiography. 
 
I. INTRODUCTION 
HE clinical gold standard in oncology for noninvasively 
assessing tumor response to therapy is measuring changes 
 
This paper was submitted for review on March 6th, 2018. Funding was 
provided by the NIH through grants R21CA184387, R44CA165621, 
R01CA170665, F31CA196216, and from pilot funding from the University of 
North Carolina Lineberger Comprehensive Cancer Center.   
J. D. Rojas was at the University of North Carolina and North Carolina State 
University (UNC-NCSU) Joint Department of Biomedical Engineering, Chapel 
Hill, NC, USA. He is now at SonoVol, Inc., Research Triangle Park, NC, USA. 
V. Papadopoulou is at UNC-NCSU Joint Department of Biomedical 
Engineering, Chapel Hill, NC, USA.  
T. J. Czernuszewicz, R. M. Rajamahendiran, and R. C. Gessner are at 
SonoVol, Inc., Research Triangle Park, NC, USA. 
A. Chytil, and W. K. Rathmell are at the Department of Medicine, Division 
of Hematology and Oncology, Vanderbilt University Medical Center, 
Nashville, TN, USA. 
Y. C. Chiang was at the UNC Lineberger Comprehensive Cancer Center, 
Chapel Hill, NC, USA. She is now at Novella Clinical, Morrisville, NC, USA. 
in tumor volume via the Response Evaluation Criteria in Solid 
Tumors (RECIST) [1]. However, functional and molecular 
changes can occur before any measurable change in tumor size. 
RECIST may not appropriately demonstrate the effect of 
therapy [2]–[6], so it is important to closely track both 
functional and anatomical changes in tumors to more quickly 
and accurately predict resistance or recurrence, and to tailor 
treatment for higher efficacy. In particular, previous work has 
shown that imaging techniques such as contrast-enhanced MRI, 
perfusion CT, and PET can predict response to antiangiogenic 
therapies earlier and track it more accurately than RECIST [2], 
[7]–[12]; however, exposure to radiation from CT and PET, and 
the cost and long imaging time of MRI, prevent these modalities 
from being ideal for serial imaging and therapy management.  
Compared to MRI, CT, and PET, ultrasound is portable, 
inexpensive, fast, and does not expose patients to ionizing 
radiation. Furthermore, Contrast-Enhanced Ultrasound (CEUS) 
is widely available and uses microbubble contrast agents 
(MCAs), which are safe for patients and have been used for 
perfusion and molecular imaging of cancer in the clinic [13]–
[16]. CEUS can provide quantitative measures of blood flow 
[17]–[19] and the expression of different biomarkers [20]–[24]. 
Additionally, studies in the past several years have shown that 
CEUS can indicate response and non-response to therapy 
before changes in tumor volume [25]–[27] and detect response 
to therapy before measurable differences in tumor volume in 
rodents with a range of tumor types [28]–[34] and in human 
patients [35]. This is of particular interest since the ability to 
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closely track disease progression may allow clinicians to tailor 
treatments for improved efficacy. 
Acoustic Angiography (AA) is another CEUS technique 
which uses the super-harmonic signals from MCAs to produce 
high-resolution maps of vasculature [36], [37]. AA takes 
advantage of the fact that tissue does not produce super 
harmonic signals to generate images of vasculature with very 
high contrast-to-tissue ratios that cannot be achieved with other 
CEUS techniques.  Furthermore, AA can provide quantitative 
measurements of vascular density, blood perfusion, and vessel 
morphology [38]–[40]. Many studies have shown that CEUS 
can be used to accurately track and predict response to therapy 
for treatment groups. Here, we use AA to predict response to 
therapy before measurable changes in tumor volume for 
individual cases with high sensitivity and specificity. 
A common clinical therapeutic strategy for the treatment of 
cancer is antiangiogenic treatment [4], [41]–[44]. Drugs such as 
Sunitinib, a small molecule multi-kinase inhibitor, reduces the 
signaling of the Vascular Endothelial Growth Factor (VEGF) 
pathway via its receptor VEGFR-2 [4], [41]–[44]. The VEGF 
pathway plays a key role in tumor angiogenesis, such that 
inhibition reduces new vessel formation and starves the tumor. 
Antiangiogenic therapy is initially effective against clear-cell 
Renal Cell Carcinoma (ccRCC), which is characterized by 
increased angiogenesis [45], [46],  although resistance to anti-
angiogenic therapy is almost universally developed after 
several months of therapy [47]–[49]. Inhibition of the Notch 
signaling pathway is an alternative strategy to antiangiogenic 
therapy that also impairs angiogenesis. Notch signaling 
promotes vessel growth while suppressing excessive sprouting 
by down regulating VEGFR-2 [50]–[52]. Thus, inhibiting 
Notch signaling produces aberrant sprouting of immature 
vasculature and has been shown to inhibit tumor growth  [51], 
[53]–[56]. These complementing inhibitory pathways provide 
an opportunity for parallel angiogenic blockade, and moreover, 
the additional expression of VEGFR-2 caused by the inhibition 
of Notch may cause this strategy to be synergistic with VEGFR-
2 inhibition.  
In this work, we hypothesize that vascular density assessment 
from AA imaging is related to tumor progression and can 
predict response to antiangiogenic and Notch inhibition 
therapies earlier than conventional measurements of tumor 
volumetric changes. Additionally, we compare the imaging-
derived metrics for tumor response to histologically derived 
measurements of blood vessel density and show they produce 
physiologically relevant information about tumor vasculature. 
Finally, we show that vascular density from AA can predict 
response to therapy with high sensitivity and specificity. 
II. METHODS 
A. Contrast Agent Formulation 
The lipid-encapsulated perfluorocarbon MCAs used in this 
work were manufactured in-house and were similar to 
commercial lipid-shelled contrast agents. The lipids 1,2-
distearoyl-sn-glycero-3-phosphocholine and 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-methoxy (polyethylene-
glycol)-2000 (DSPE-PEG2000) in a 9:1 M ratio and a total lipid 
concentration of 1.0 mg/mL were dissolved in a solution of 
phosphate-buffered saline, propylene glycol, and glycerol 
(16:3:1). Then, 1.5 mL of the solution was added to a 3-mL 
glass vial and the head space was gas-exchanged with 
Decafluorobutane gas. Microbubbles (1 µm mean diameter and 
a 1x1010 #/mL concentration) were produced by using an 
agitation technique. 
B. Xenograft and Treatment Protocol 
A total of 32 NSG (NOD/scid/gamma) female mice (Mus 
musculus) were injected subcutaneously in the flank with 
8x106 786-O human ccRCC cells. Mice were initially separated 
into 4 groups: VEGFR-2 inhibitor SU (Sunitnib malate, 
Selleckchem, TX, USA), a combination of SU and the Notch 
pathway inhibitor GSI (Gamma secretase inhibitor, PF-
03084014, Pfizer, New York, NY, USA), a Switch group which 
would be treated with SU and switched to the Combo treatment 
after 3 weeks, and Control (100 µL of saline). However, it was 
decided after the start of treatment that the Switch treatment 
would be explored in a separate larger study, so the Switch mice 
were added to the SU group and remained on SU treatment. 
Therefore, the final number of animals in each group were 8, 
14, and 7 for the Control, SU, and Combo groups, respectively. 
The mice in the SU group were administered 50 mg/kg of SU, 
while the mice in the Combo group were given a combination 
of 50 mg/kg of SU and 90 mg/kg of GSI by oral gavage. The 
volume of the tumors was measured using calipers every 2 days 
and treatment commenced for four weeks once the tumors 
reached a size of 200 mm3. Injection, treatment, and imaging 
protocols were approved by UNC Institutional Animal Care and 
Use Committee (IACUC). 
C. Animal Preparation Protocol and Contrast Administration 
Imaging started with a pre-treatment scan once the tumors 
reached a size of 150 mm3 and continued once per week until 
the end of treatment. During each imaging session, the mice 
were anesthetized with 1.5 % isoflurane and warmed with a heat 
lamp to maintain body temperature. The area around the tumor 
was shaved using an electric razor and further depilated with a 
chemical hair remover. A 27-gauge catheter was inserted into 
the tail vein for the administration of MCAs, which were 
continuously infused at a rate of 1.5x108 bubbles/min. 
D. Imaging System 
The imaging system used for this work was a VegaTM 
platform (SonoVol, Inc., Research Triangle Park, NC), which 
allows for automated 3D ultrasound image acquisition from 
mice.  The system was used in both high-frequency/high-
resolution B-mode (24 MHz) for anatomical reference and AA 
mode (transmit 2 MHz with a 1.1 MPa peak-negative pressure, 
receive 24 MHz) for microvascular analysis.  Further details of 
this system have been previously described in [57]. 
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E. Imaging Protocol 
A 3D B-mode “scout scan” with an elevational resolution of 
200 µm of was used to locate the tumor. Next, AA images were 
captured around the tumor location 30 seconds after the start of 
the MCA infusion.  AA imaging consisted of a continuous 
sweep acquisition, which produced images of vasculature with 
an elevational resolution of around 500 µm. The tumor was 
scanned 16 times, allowing MCAs to reperfuse into the tissue 
for 10 seconds between each scan, and a final AA image was 
computed by averaging all the acquisitions.   
 
F. Noninvasive Measurements of Tumor Size and Vascular 
Density 
Tumor ROIs were manually segmented using SonoEQTM 
(SonoVol, Inc., Research Triangle Park, NC) analysis software 
from B-mode anatomical reference images. Blood vessel 
density (BVD), or the percentage of the tumor that had 
measurable perfusion, was computed from the AA 
microvasculature images by dividing the number of voxels with 
intensity values higher than a fixed, predetermined threshold by 
the total number of voxels in the ROI. The tumor volume was 
calculated by summing the number of voxels inside the ROI and 
multiplying by the spatial dimensions of a voxel. 
G. Organization of Volume and Density Data 
The mice started treatment at different days, since the dosing 
began once the tumors reached 200 mm3, so that imaging time 
points for different animals correspond to different days 
before/after the start of treatment. Therefore, the imaging time 
points that were captured before the start of treatment were 
binned into a baseline (-1) week, those that occurred between 1 
and 7 days after the start of treatment were binned into week 1 
of imaging, 8-14 days into week 2, 15-21 days into week 3, and 
22-28 days after the start of treatment into week 4 of imaging. 
H. Histological Assessment of Vessel Density 
CD31 immunohistochemistry was performed to serve as a 
gold standard for comparison against imaging results. Tumors 
were surgically extracted at necropsy, which occurred after the 
last imaging time point or earlier if the size limit was exceeded. 
Three tumors from each treatment group were used for the 
histological analysis, except for the SU group from which 6 
tumors were used. Immunohistochemistry was performed on 
paraffin-embedded tumor sections on a Leica Bond Max auto-
stainer using anti-CD31 from Novocastra (cat # NCL-CD31-
1A10). Following heat-induced epitope retrieval in EDTA for 
20 min, the antibody was incubated on the tissue for 1 h at a 
dilution of 1:100 then visualized with diaminobenzidine 
(DAB). Serial stained sections from each treatment group (10 
sections per tumor) were digitized by an Olympus DP 72 
(Olympus Corporation, Center Valley, PA) or an Infinity2 
 
Fig 1. Representative vessel density images from the different treatment groups. Representative images are displayed at the beginning (left) and end (right) of the
study. In each panel, the image on the left is a cross-section of the tumors while the image on the right (dashed square) is a coronal view. The scale bar represents
1 cm.  Yellow indicates microvasculature acquired in AA mode.  The blue outlines the tumor region of interest, and was derived via registered anatomical B-mode
images (not shown).  
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camera at 200x, and the percentage of positively stained area 
was determined using ImageJ [58]. 
I. Statistical Analysis 
A right-tailed Spearman test was used to assess the 
correlation between the last imaging BVD timepoint and 
histology for different threshold values in order to select the 
most appropriate threshold. A Kruskal-Wallis analysis with 
Tukey multiple comparison post-test was performed to 
determine if the BVD or volume were significantly different 
between the treatment groups over the time-course of the study. 
Significance was set at p < 0.05. 
Furthermore, the BVD at early time points was used to 
predict response to treatment (treated vs untreated, inferred 
from the tumor volume at later time points). The BVD around 
day 7 (day 6 to 10) after the start of treatment was plotted 
against the corresponding tumor volume measurements from 
around day 21 (day 17 to 24). A linear regression model was 
used to fit the data, so that a predicted tumor volume (PTV) for 
each animal could be calculated from the BVD around day 7. 
Next, PTV values above and below a threshold were classified 
as untreated or treated, respectively, for a range of thresholds. 
Using receiver-operator curve (ROC) analysis, the PTV 
threshold that produced the best sensitivity (true positive) and 
specificity (true negative) at separating treated and untreated 
was calculated. 
III. RESULTS 
Fig 1 shows representative BVD images for each treatment 
group before the start of treatment and at the end of the study. 
At the pretreatment time-point, all tumors were well perfused 
(blue line indicates boundary, yellow indicates MCA). Over the 
duration of the study, untreated tumors in the control group (top 
row) exhibited continued growth without significant vascular 
changes, while the SU and Combo treated tumors (middle and 
bottom row, respectively) saw stunted growth and a marked 
decrease in MCA signal density and intensity, indicating 
vascular disruption. 
Due to unknown health issues, tumor size limitations, and 
inability to insert the catheter into the tail vein for contrast 
administration, the different imaging weeks had varying 
numbers of mice (Table 1). Only control animals were 
sacrificed because of tumor burden, and euthanasia was the 
only reason for the decrease in group size, except for one 
catheter failure on week 2. For the treatment groups, 6 SU and 
3 Combo mice died before the end of treatment, and some mice 
were not imaged because they were not stable under anesthesia 
or a catheter could not be inserted into the tail vein (also likely 
due in part to therapy side-effects including dehydration and 
weight loss). This resulted in all the Combo and Control mice, 
and 86% (on average) of the SU mice that were still alive to be 
imaged at each timepoint.  
A. Assessing Response to Therapy 
Quantitative assessment of tumor response to therapy is 
depicted in Fig 2. The BVD for the Combo and SU groups were 
significantly lower (p < 0.05) from the Control after only a 
week of treatment, while it took 2 weeks for the volumes to 
become significantly different between the groups (Fig 7). The 
BVD for the Combo group remained significantly lower from 
that of the Controls for the remainder of the study, and although 
the SU group had a lower median BVD value than the Control 
group, the difference was not statistically significant after the 
first week of treatment. 
 
B. Using Volume and Density for Classification of Treatment 
The volume measurements of all mice at every imaging time 
point after the start of treatment were plotted against the 
corresponding BVD values (Fig 3), and a line with a fixed y-
intercept was used to classify the data points as treated (under 
TABLE I 
NUMBER OF ANIMALS IMAGED FOR EACH TREATMENT WEEK. 
 Imaging Week 
 -1 1 2 3 4 
Control 8 8 6 6 4 
SU 12 10 11 12 8 
Combo 6 6 5 6 4 
 
Fig 2.  Tumor volume and blood vessel density for the different imaging weeks. The vessel density (right) of the SU and Combo groups became significant (p <
0.05) from the Controls 1 week after the start of treatment, while it took 2 weeks for a significant difference in volume (left) to emerge. Significance is denoted
by the horizontal bars. 
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line) or untreated (above line). Using the slope as a classifier, 
the sensitivity and specificity for a range of slopes were 
calculated. Setting the slope at -0.06 %/mm3 (shown in Fig 3), 
the sensitivity and specificity were 89% and 92%, respectively, 
at classifying the control group from the treated groups. 
Moreover, when the same slope was used to classify the Control 
group from the SU and Combo groups individually, the 
sensitivity was 84% and 100% for SU and Combo, respectively.  
When only the data from week 1 was used for the analysis 
(Fig. 3b), the sensitivity and specificity were 84% and 88% 
when classifying between treated and untreated, and the 
sensitivity was 75% and 100% for the SU and Combo, 
respectively, when the Controls were classified against each 
group individually. 
C. Validation of Vessel Density Measurement Using Histology 
The histological results collected after 4 weeks of treatment 
demonstrate that the amount of CD31 neovasculature via 
staining in the tumors for the SU and Combo groups was 
significantly lower (p < 0.05) than that of the Controls (Fig 4). 
The stained area was quantified and compared to the BVD 
results, and a strong correlation was demonstrated (Fig 5). 
Furthermore, the correlation coefficient ρ was similar between 
the users (ρ = 0.77 ± 0.03). These results confirm that vascular 
density measurements acquired through AA imaging correlate 
with histological vascular density measurements. 
D. Assessing Response to Treatment 
The relationship between BVD around day 7 versus tumor 
volume around day 21 had a significant correlation (p < 0.001) 
and a spearman coefficient of 0.82 (Fig 6). An ROC curve was 
plotted using different PTV thresholds found using the equation 
of the linear fit model (Fig 6a) and the BVD values from around 
7 days after the start of treatment (Fig 6b), and the curve 
indicates that a maximum sensitivity and specificity of 94% and 
86%, respectively, can be obtained when using a PVT threshold 
value of 705 mm3. Therefore, the results show that BVD can be 
used to differentiate between treated and untreated tumors for 
individual mice with strong confidence.  
IV. DISCUSSION 
In this work, data supports our hypothesis that BVD derived 
from microvascular imaging can evaluate tumor response to 
therapy earlier than conventional tumor volume measurements, 
in a rodent model of renal cell carcinoma treated with 
antiangiogenic and Notch inhibition therapies.  
It is important to accurately and closely track response to 
therapy of tumors to minimize undesirable side effects of 
chemo or radiotherapy if treatment begins to fail.  Furthermore, 
the array of available therapies for ccRCC is expanding rapidly, 
creating a scenario where selecting therapy for an individual 
patient will be more relevant than ever. Conventional methods 
for evaluating response to therapy typically rely on changes of 
tumor volume, typically at an interval of 3 months, but tracking 
volume has been shown to be inaccurate and often underreports 
the effect of therapy. Imaging techniques such as dynamic 
contrast-enhanced MRI and metabolic PET imaging have been 
shown to be effective at tracking and predicting response to 
therapy by providing functional insights rather than simple 
changes in tumor volume.  These modalities are associated with 
challenges such as lack of bedside support, cost, contrast 
contraindications (MRI), and requirements for access to short-
lived isotopes (PET).  In contrast, CEUS is inexpensive, 
portable, and safe for repeated serial imaging.  Here we 
demonstrate that vascular density measurements from AA 
correlate well with histology and can detect response to therapy 
earlier than changes in tumor volume.  Admittedly, current AA 
microvascular imaging is limited to within a few centimeters of 
depth, and therefore performs best in rodents, however, future 
advancements may enable this or similar ultrasound 
microvascular techniques such as super-resolution imaging 
[59]–[61] for deeper clinical imaging. 
The data illustrate that microvascular assessment in 
conjunction with volume measurements can classify tumors as 
treated or untreated with very high sensitivity and specificity 
(Fig 3). The results suggest that a tumor can be correctly 
classified a responder to therapy regardless of its size or 
Fig 4.  Representative CD31 staining images of the different treatment groups and Stained Area results. The SU and Combo groups had significant values (p < 
0.05) from the Control group. SU and Combo groups were not statistically significantly different from each other. 
Fig 5.  Correlation plot of image derived blood vessel density (BVD) vs CD31
stained neovasculature. The results show strong correlation (ρ = 0.75) between
imaging and histology. Dotted line indicates the linear regression line. The
black arrow is pointing towards an outlier measurement in the plots that reduces
the strength of the correlation. 
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duration of treatment with a high degree of confidence. 
Sensitive classification can be accomplished within a week of 
the start of treatment, which cannot be accomplished with 
tumor volume measurements alone, and can be beneficial for 
clinical applications. While the sensitivity of classifying the 
tumors treated with SU is only about 75% at week one, every 
tumor treated with the combination therapy was correctly 
classified at the week 1 time point (Fig 3). Furthermore, the 
BVD values from around day 7 can be used to predict treatment 
response with a high degree of confidence before tumor volume 
measurements become significantly different (Fig 6). Although 
survival outcomes would need to be tracked in order to relate 
the observed changes in tumor properties to successful or failed 
treatment, initial results about our ability to assess a tumor’s 
response to treatment compared to controls based on 
microvascular density prior to volume measurements were 
encouraging.  
Histological validation demonstrated that the relative 
correlation between image based vascular density and vascular 
density from histology was high (Fig 5), but the value ranges of 
the two metrics were vastly different.   The explanation for this 
discrepancy lies in the resolution of the two techniques. While 
optical microscopy, which was used for the histological 
analysis, can resolve individual capillaries, AA ultrasound 
imaging utilized here will blur any vessels smaller than the 
resolution of 100-150 µm in diameter into the entire image 
voxel, indicating a higher vascular density than optical 
histology analysis. 
There was a strong correlation between imaging results and 
histology (ρ = 0.75), however, a single data point indicated by 
the arrow in Fig 5 reduces the correlation, and when it is 
removed from the analysis, ρ is 0.9. This suggests that this point 
was a substantial outlier, and it is likely that a higher correlation 
overall may be achieved than reported in this study if a larger 
data set is utilized.  
Surprisingly, only 50% of the mice in the SU and Combo 
Fig 3.  Plot of BVD vs volume for all datapoints. The two plots display the points after the start of treatment (a) and only those at week 1 (b). A line with a y-
intercept set at 100% BVD (black dotted line) can be used to separate the data between treated (under the line) and untreated (above the line). 
Fig 6.  Linear regression model used to calculate predicted tumor volume (PTV) and ROC curve for PTV as a classifier. Plot (a) shows the linear regression model 
(dashed black line) of BVD vs tumor volume used to calculate PTV, and plot (b) shows the ROC curve for PTV as a classifier of treated and untreated tumors. 
the black filled in circle in the ROC curve represents the PTV threshold with the highest sensitivity (94%) and specificity (86%) and corresponds to a value of 705
mm3. The dashed line in (b) represent a random chance (50%) of correctly classifying the data. 
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groups survived the entire study (Table 1). There is no work 
reporting this rate of morbidity as a result of the drugs used 
here, and a recent study using the same tumor model, 
therapeutics, and dosage demonstrated no negative health 
effects on the animals [28]. It is unclear what effect the health 
issues of the mice had on the results of the study, but the 
findings of this work agree with those of previous studies which 
used similar treatment strategies [27]–[29], [34]. In addition to 
the loss of mice due to health issues, the Control mice grew 
quickly and were euthanized once the tumors reached the size 
limit so that only ~50% of mice in that group remained at the 
week 4 time point. Therefore, the diminishing number of mice 
in the groups probably contributed to the lack of significance in 
the BVD between the Control and SU groups after the first 
week of imaging, even though the values appeared to be 
different (Fig 7). Another reason why the BVD of the SU and 
Control groups was not significant at the end of the study, 
unlike the histological results, is that the binning of data into 
weeks results in mice that have been treated for varying 
amounts of time to be grouped into the same week (e.g. 14 days 
and 20 days were binned into week 2 of treatment), which likely 
introduced additional variability. Furthermore, while the BVD 
values being compared for each group was small (around 4 per 
group) at the last time point, 30 histology images for each group 
were used for analysis. 
Detecting response to therapy using imaging one week 
earlier than changes in tumor volume does not seem substantial, 
however, while rodent cancer evolution has a timescale of days 
to weeks, it takes several weeks to several months to observe 
response to therapy in humans [2], [9], [62]. Therefore, a 
difference of a week in mice may translate to more clinically 
relevant time scales in humans.   
Lastly, the results of this work, and previous work showing 
that GSI may not be a good treatment alternative [28], 
demonstrate that a combination of SU and GSI provides a better 
strategy for angiogenic suppression than delivering either drug 
individually. The volume results demonstrate that while the SU 
group had reduced tumor growth from the Controls, the Combo 
group alone caused the stagnation of tumor growth, and in some 
cases produced a reduction in tumor volume (Fig 7). 
V. CONCLUSION 
In this work, we demonstrate that an ultrasound metric of 
vascular density can be used to assess the response of ccRCC 
tumors to antiangiogenic and Notch inhibition therapies earlier 
than tumor volume, which is the clinical gold standard. This 
application of contrast enhanced ultrasound has important 
merits as a variety of targeted and immunotherapy agents crowd 
the treatment landscape of ccRCC. Furthermore, the results 
demonstrate that vessel density measurements can classify 
between treated and untreated tumors and predict response to 
therapy early in the treatment with high sensitivity and 
specificity.  Future studies will need to be performed in humans 
to establish if these findings carry over to a clinical population. 
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